Equities analysts expect that Monopar Therapeutics Inc. (NASDAQ:MNPR) will post earnings per share of ($0.15) for the current quarter, according to Zacks. Zero analysts have made estimates for Monopar Therapeutics’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.17). Monopar Therapeutics reported earnings per share of ($0.13) during the same quarter last year, which would indicate a negative year over year growth rate of 15.4%. The business is expected to announce its next quarterly earnings results on Friday, March 26th.
According to Zacks, analysts expect that Monopar Therapeutics will report full year earnings of ($0.54) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.52). For the next financial year, analysts expect that the firm will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.37) to ($1.04). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Monopar Therapeutics.
Separately, Roth Capital initiated coverage on Monopar Therapeutics in a research report on Thursday, January 28th. They set a “buy” rating and a $49.00 price objective for the company.
In related news, major shareholder Tactic Pharma Llc sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $14.64, for a total value of $1,830,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 48.40% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Monopar Therapeutics stock. BlackRock Inc. boosted its holdings in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 99.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,391 shares of the company’s stock after buying an additional 2,688 shares during the period. BlackRock Inc.’s holdings in Monopar Therapeutics were worth $33,000 as of its most recent SEC filing. 0.66% of the stock is currently owned by hedge funds and other institutional investors.
About Monopar Therapeutics
Monopar Therapeutics Inc, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers.
See Also: Why do corrections happen?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.